Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27398620 | 1.00 | SLC18A3 (0.38) | SLC18A3SIGMAR1POLBHRH3MEN1 | |
| SCHEMBL22593578 | 0.90 | CA2 (0.41) | SLC18A3SIGMAR1POLBHRH3MEN1 | |
| SCHEMBL27398613 | 0.86 | MEN1 (0.42) | HRH3MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL30329419 | 0.86 | CA2 (0.40) | SLC18A3SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL23085113 | 0.85 | SLC18A3 (0.35) | SLC18A3SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL25162267 | 0.85 | SLC18A3 (0.35) | SLC18A3SIGMAR1POLBMEN1KMT2A | |
| SCHEMBL27398776 | 0.85 | SLC18A3 (0.35) | SLC18A3SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL25703421 | 0.84 | SIGMAR1 (0.37) | SLC18A3SIGMAR1 | |
| SCHEMBL20506805 | 0.84 | SLC18A3 (0.49) | SLC18A3SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL20506803 | 0.84 | SLC18A3 (0.49) | SLC18A3SIGMAR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983020-B1 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-06-26 | — | — | EP | disclosed |
| US-20230192853-A1 | CD8 BINDING AGENTS AND USES THEREOF | GENENTECH, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2021046159-A1 | CD8 BINDING AGENTS AND USES THEREOF | GENENTECH, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2020256546-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192853-A1 | CD8 BINDING AGENTS AND USES THEREOF | CD81, CD4, HAVCR2 | SLC18A3 1530/4885SIGMAR1 3502/4885POLB 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.